Indeed, pharmacological reduction of the genetic modifier NCALD using ASOs in combination with suboptimal dose of SMN-ASO has shown to ameliorate SMA pathology hallmarks in SMA mice at PND21. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.